Cargando…
Myocarditis and myositis/myasthenia gravis overlap syndrome induced by immune checkpoint inhibitor followed by esophageal hiatal hernia: A case report and review of the literature
Immunotherapy with programmed death 1 (PD-1) inhibitor has shown activity as first- or second-line treatment for various metastatic human malignancies. Immune-related adverse events (irAEs) are now well-described, and most organ sites are potentially influenced, but the prevalence of myocarditis and...
Autores principales: | Yin, Beibei, Xiao, Junjuan, Wang, Xuan, Li, Xingyu, Guan, Yaping, Chen, Jinghua, Han, Pengxi, Li, Kun, Wang, Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9705572/ https://www.ncbi.nlm.nih.gov/pubmed/36457566 http://dx.doi.org/10.3389/fmed.2022.950801 |
Ejemplares similares
-
Myocarditis-myositis-myasthenia gravis overlap syndrome depending on immune checkpoint inhibitor
por: Ünlütürk, Zeynep, et al.
Publicado: (2023) -
Nivolumab-Induced Myasthenia Gravis Concomitant With Myocarditis, Myositis, and Hepatitis
por: Bawek, Sawyer J, et al.
Publicado: (2021) -
Case Report: The Neuromusclar Triad of Immune Checkpoint Inhibitors: A Case Report of Myositis, Myocarditis, and Myasthenia Gravis Overlap Following Toripalimab Treatment
por: Luo, Yue-Bei, et al.
Publicado: (2021) -
Immune checkpoint inhibitor induced myocarditis, myasthenia gravis, and myositis: A single‐center case series
por: Longinow, Joshua, et al.
Publicado: (2022) -
Durvalumab-induced myocarditis, myositis, and myasthenia gravis: a case report
por: Cham, Jason, et al.
Publicado: (2021)